Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-274-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$154.58 million
Profitability
Miscellaneous
Employees255
OptionableOptionable
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) posted its quarterly earnings data on Wednesday, October, 24th. The biotechnology company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.29. The biotechnology company had revenue of $78.49 million for the quarter, compared to the consensus estimate of $78.84 million. Sarepta Therapeutics had a negative return on equity of 23.67% and a negative net margin of 89.46%. View Sarepta Therapeutics' Earnings History.
When is Sarepta Therapeutics' next earnings date?
What price target have analysts set for SRPT?
25 analysts have issued 12-month price targets for Sarepta Therapeutics' shares. Their forecasts range from $95.00 to $275.00. On average, they anticipate Sarepta Therapeutics' share price to reach $184.2857 in the next year. This suggests a possible upside of 50.1% from the stock's current price. View Analyst Price Targets for Sarepta Therapeutics.
What is the consensus analysts' recommendation for Sarepta Therapeutics?
25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 2 hold ratings and 23 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sarepta Therapeutics.
What are Wall Street analysts saying about Sarepta Therapeutics stock?
Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.42, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.4%, and tax rate of 15% beginning in FY 2024." (1/4/2019)
- 2. According to Zacks Investment Research, "Sarepta's sole marketed drug Exondys 51 has witnessed impressive growth so far this year. Sarepta is also focused on reimbursement programs for better accessibility of the drug. The company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping and gene therapy pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, remains a concern. Moreover, approval for Exondys 51 in the EU is likely to be delayed due to negative CHMP opinion. The DMD market is getting competitive as several other companies are developing treatments. Notably, the company’s shares have outperformed the industry in the past year." (1/5/2019)
- 3. Cantor Fitzgerald analysts commented, ": Reiterating our Overweight rating and $217 PT which is 12-month upside of 82% after current weakness. In this report, we discuss our expectations for upcoming pivotal design for the company’s micro-dystrophin program expected before year-end. We think that the regulator-approved design will be in line with Sarepta’s guidance. Bigger picture, Sarepta remains a top franchise pick over 2019, as we think the company still has catalysts beyond micro-dystrophin that are unappreciated by the Street. Key catalysts in 1Q19 will be limb girdle 2E data in first three patients and next-generation PPMO chemistry readout." (11/26/2018)
Has Sarepta Therapeutics been receiving favorable news coverage?
Media headlines about SRPT stock have been trending extremely positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sarepta Therapeutics earned a media sentiment score of 4.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY) and Bausch Health Companies (BHC).
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Mr. Douglas S. Ingram, Pres, CEO & Director (Age 56)
- Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 54)
- Mr. David Tyronne Howton Jr., Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)
- Mr. Alexander Bo Cumbo, Sr. VP & Chief Commercial Office (Age 48)
- Dr. Edward M. Kaye, Advisor (Age 70)
Who are Sarepta Therapeutics' major shareholders?
Sarepta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.02%), State of Alaska Department of Revenue (0.01%), Boston Advisors LLC (0.01%), Vanguard Capital Wealth Advisors (0.01%), Nisa Investment Advisors LLC (0.00%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Richard Barry, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.
Which major investors are selling Sarepta Therapeutics stock?
SRPT stock was sold by a variety of institutional investors in the last quarter, including Boston Advisors LLC and Vanguard Capital Wealth Advisors. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell, Richard Barry and Sandesh Mahatme. View Insider Buying and Selling for Sarepta Therapeutics.
Which major investors are buying Sarepta Therapeutics stock?
SRPT stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Meeder Asset Management Inc., Nisa Investment Advisors LLC, State of Alaska Department of Revenue and Cornerstone Advisors Inc.. View Insider Buying and Selling for Sarepta Therapeutics.
How do I buy shares of Sarepta Therapeutics?
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of SRPT stock can currently be purchased for approximately $122.80.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $8.21 billion and generates $154.58 million in revenue each year. The biotechnology company earns $-50,680,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Sarepta Therapeutics employs 255 workers across the globe.
What is Sarepta Therapeutics' official website?
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
